David Hutton

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept at this year's American Academy of Ophthalmology meeting.

In the study, researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and surviving into the eye’s retina.

The company also completes enrollment of the multiple ascending dose phase of AMARONE, the first clinical trial of EyeBio’s lead investigational asset Restoret, with favorable initial safety and tolerability at all dose levels.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

According to the companies, the merger creates a NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia.

Loretta Alborghetti, from Redditch, UK, a medical secretary within the ophthalmology department at Worcestershire Acute Hospitals NHS Trust, illegally accessed the records of more than 150 patients.

Charles Wykoff, MD, PhD, spoke with Ophthalmology Times about the GALE study data at one year looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Researchers found reduced iron concentration in the clear gel part of the eye of human patients and iron accumulation in the retina of mice.

Mariam Maghribi, Chief Business Officer for Shifamed, spoke with Ophthalmology Times about the Atia Vision IOL device at this year's American Academy of Ophthalmology meeting.

ATSN-101, a gene therapy for GUCY2D-associated Leber congenital amaurosis, has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial.

Nick Curtis, CEO at LENSAR, met with Ophthalmology Times to discuss their co-development with Oertli on their phaco device and LENSAR's Ally treatment system at the American Academy of Ophthalmology.

TRS01 has the potential to be the first-line treatment option for non-infectious uveitis and specifically uveitic glaucoma, according to the company.

Rick Lewis, MD, Chief Medical Officer for ViaLase met with Ophthalmology Times to discuss completion of their important pivotal trial called VIA-002, which is a randomized prospective trial of the use of the ViaLase Laser versus SLT in adult patients with primary open angle glaucoma at the American Academy of Ophthalmology.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Researchers found the growth of RPE cells was successfully controlled by the stencil patterns. When RPE cells were not held together correctly, the cells excreted levels of harmful proteins that could contribute to vision loss.

According to the company, OCU410ST uses an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene.

Clara Chan, MD, FRSCS, FACS, DABO, from the University of Toronto spoke with Ophthalmology Times about their study on the consistency of outcomes across 3 different cohorts of patients that were internationally collected at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Jayashree Kalpathy-Cramer, PhD, was granted $300,000 from the Michael J Fox Foundation to examine key data put together at the Sue Anschutz-Rodgers Eye Center with artificial intelligence in an effort to identify biomarkers of Parkinson’s disease.

Swarup Swaminathan, MD, spoke with Ophthalmology Times about using the Heidelberg SPECTRALIS and caring for our Glaucoma patients at this year's American Academy of Ophthalmology meeting.

Daniel Chang, MD, spoke with Ophthalmology Times about his poster "Clinical performance of a diffractive, extended depth-of-focus IOL, with violet light filtering and high-resolution lathing" at this year's American Academy of Ophthalmology meeting.

Researchers from Anglia Ruskin University and the University of Oxford conducted a study that reveals knowledge gaps for conditions that affect 18-64-year-olds in the UK.

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

Ben Bergo, CEO of Visus Therapeutics spoke with Ophthalmology Times about the study on presbyopia, BRIO-I at this year's American Academy of Ophthalmology meeting.